Cargando…
Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807308/ https://www.ncbi.nlm.nih.gov/pubmed/33457220 http://dx.doi.org/10.21037/tau-20-907 |
| _version_ | 1783636713817505792 |
|---|---|
| author | Poletajew, Sławomir Krajewski, Wojciech Kryst, Piotr |
| author_facet | Poletajew, Sławomir Krajewski, Wojciech Kryst, Piotr |
| author_sort | Poletajew, Sławomir |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7807308 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78073082021-01-15 Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? Poletajew, Sławomir Krajewski, Wojciech Kryst, Piotr Transl Androl Urol Editorial Commentary AME Publishing Company 2020-12 /pmc/articles/PMC7807308/ /pubmed/33457220 http://dx.doi.org/10.21037/tau-20-907 Text en 2020 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Poletajew, Sławomir Krajewski, Wojciech Kryst, Piotr Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title_full | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title_fullStr | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title_full_unstemmed | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title_short | Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| title_sort | behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807308/ https://www.ncbi.nlm.nih.gov/pubmed/33457220 http://dx.doi.org/10.21037/tau-20-907 |
| work_keys_str_mv | AT poletajewsławomir behindapersonalizedtherapywithimmunecheckpointinhibitorsinmetastaticbladdercancerreadyforaprimetime AT krajewskiwojciech behindapersonalizedtherapywithimmunecheckpointinhibitorsinmetastaticbladdercancerreadyforaprimetime AT krystpiotr behindapersonalizedtherapywithimmunecheckpointinhibitorsinmetastaticbladdercancerreadyforaprimetime |